Investival ShowcaseMonday, 17 November 2025 - GMT (Greenwich Mean Time, GMTZ)

2025 has been a year of economic uncertainty amid a changing geopolitical and macroeconomic stress. Our panel of investment experts discuss how Europe is responding to the global challenges and how we can make Europe a fertile ground for innovation.

• Europe’s current state, opportunities, strengths and challenges

• Addressing the persisting early-stage funding gaps and how to meet the high bar for financing

• China as a rising force – how does Europe & US compare?

• The Impact of AI and digital health on investment patterns across regions

• Strategies for European companies to attract global investment

The US has long been considered the place to be in the life sciences space given the market size and more attractive investment and reimbursement landscapes. Join US market access experts as they discuss the changing US political landscape and how to find success across the pond.

• Accessing US capital markets 

• Strategic partnerships with American investors 

• The importance of having US based stakeholders and how to lead a transatlantic team

• Navigating FDA requirements for European companies 

The past 18 months have seen a shift in life sciences M&A, with fewer deals at higher values being completed. Here experts will explore the reasons for the shift and how to best position your company for a fair and efficient acquisition.

• Latest M&A trends in life sciences 

• Factors affecting deal valuation 

• Strategies to attract strategic buyers 

With the IPO boom of 2020 and 2021 leaving investors burnt by falling share prices there has been scepticism surrounding taking life science companies public. Join us as our panel discuss when and how to consider an IPO to provide the greatest chances of success in the public market.

• IPO readiness and timing 

• Pros and cons of the European and US public markets

• Post-IPO considerations and investor relations 

• SPAC opportunities and alternative listing routes 

The AI landscape continues to evolve, integration in life science startups is becoming commonplace. As artificial intelligence continues to promise revolutionary advances, investors and partners face critical questions about demonstrable value, investment priorities, and whether the AI boom has reached its peak. Join us as our experts discuss AI adoption, exploring both breakthrough potential and persistent challenges in this rapidly evolving field.

• How can life science startups effectively prove the value of their AI technologies beyond the hype?

• The value of being an AI forward life science company, has investor enthusiasm peaked?

• The future of AI for strategic players, are big pharma and Tier 1 medtechs developing AI tools in-house or looking externally for innovation?

The so called “valley of death” between early and late-stage funding continues to prove a critical risk to life science companies. With venture capital funds unable to support the entire industry on their own, alternative funding sources are on the rise. Learn more about the differences between traditional and novel funding sources and what is best for your company.

• Structured financing options, royalty financing and venture debt

• How private equity differs from traditional VC funding

• Strategic partnerships and licensing deals 

Recent reports have highlighted the evolving role of large strategics in powering innovation in life science. With a possible shift away from internal R&D, big pharma and tier 1 medtechs are looking for external innovation to drive growth in their business units. Join our panel of CVC leaders as they discuss their process and rationale for investment and strategies for getting in front of these global giants.

• Strategic vs. financial investment approaches 

• CVC investment criteria and focus areas 

• Building successful CVC partnerships